Post Herpetic Neuralgia Therapies Market, by Drug Class (Non-Opioid Analgesics, Opioids, Anti-convulsants, Selective Serotonin and Norepinephrine Reuptake Inhibitors (SSRIs), Anesthetic Agents, Antidepressants), by Drug Type (Prescription-based, Over-the-counter Drug) and, by Application (Hospitals, Clinics, Home Care, Others): Opportunity Analysis and Industry Forecast, 2023-2032

Scope of the Study

For the purpose of analysis, the report covers a micro-level study of different by drug class, by drug type, by application. The analysis presented in this section elaborates the attractiveness of each region to identify the lucrative market areas for investment. Region-wise, the report includes the Post herpetic neuralgia therapies market trends across North America, Europe, Asia-Pacific, and LAMEA. In addition, the study covers quantitative analysis for Post herpetic neuralgia therapies market from 2023 to 2032. The CAGR is calculated for 2024 to 2032, considering all the macro- and micro-economic factors, which impact the growth of the Post herpetic neuralgia therapies market.

Market Landscape

The study comprises parent/peer market analysis, patent analysis, pricing analysis, top player positioning in the base year, Porter’s five force analysis, value chain analysis, impact of government regulations on the market, and market dynamics (drivers, restraints, and opportunities), which directly or indirectly impact the growth of the market.

The Post herpetic neuralgia therapies market is segmented on the basis of by drug class, by drug type, by application.

Post herpetic neuralgia therapies market Revenue (%), By type

Regional Analysis

The Post herpetic neuralgia therapies market is analyzed across four key regions, which include North America, Europe, Asia-Pacific, and LAMEA. The key countries contributing toward the growth of the market include:

• North America: U.S., Canada, and Mexico

• Europe: Germany, UK, Italy, Spain, France, and rest of Europe

• Asia-Pacific: India, China, Japan, South Korea, Australia, and rest of Asia-Pacific

• LAMEA: Brazil, Saudi Arabia, South Africa, and rest of LAMEA

Key companies identified in the report are Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Johnson and Johnson, Pfizer Inc., Eli Lilly and Company, Mylan N.V., Novartis AG, Purdue Pharma L.P., Sanofi, Sun Pharmaceutical Industries Ltd.

Research Methodology

AMR offers its clients with comprehensive research and analysis based on a wide variety of factual inputs, which majorly include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models refine the data & statistics and enhance the accuracy of our recommendations and advice.

Key Questions Answered in AMR’s Post herpetic neuralgia therapies market Report

The Post herpetic neuralgia therapies market analysis covers in-depth information of major industry participants. Porter’s five forces analysis helps analyze the potential of buyers & suppliers and the competitive scenario of the industry for strategy building. Major countries have been mapped according to their individual revenue contribution to the regional market. The comprehensive report on Post herpetic neuralgia therapies market addressed critical questions for the players operating in the market or planning to enter in the market, and help them to take strategic decisions.

• How do you see the growth of Post herpetic neuralgia therapies market in the next five years?

• What are the top winning strategies adopted by the leading players operating in the market?

• Who are the targeted customers in the Post herpetic neuralgia therapies market?

• Who are the major players in the Post herpetic neuralgia therapies market

Key Insights Of Post herpetic neuralgia therapies market Report

• AMR helps analyze the value chain of a particular market from all stakeholder’s perspectives

• The study includes Porter’s five forces analysis to understand the competitive scenario of the industry and role of each stakeholder

• Market dynamics includes drivers, restraints, and opportunities of the market. Drivers state the factors that boost the growth of the market, whereas restraints are the factors that are likely to hamper the market growth. Opportunities are the factors that act as the catalysts of the market. All these factors, along with data facts, are covered in the study

• The parent/peer market analysis helps in understanding the parent market, and estimate the share of the Post herpetic neuralgia therapies market in the parent market. In some cases, it exhibits a comparative share analysis between Post herpetic neuralgia therapies market and its peer products.

  Post Herpetic Neuralgia Therapies Market, by Drug Class Report Highlights

Aspects	Details
By Drug Class	Non-Opioid Analgesics Opioids Anti-convulsants Selective Serotonin and Norepinephrine Reuptake Inhibitors (SSRIs) Anesthetic Agents Antidepressants
By Drug Type	Prescription-based Over-the-counter Drug
By Application	Hospitals Clinics Home Care Others
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players	Sun Pharmaceutical Industries Ltd., Sanofi, GlaxoSmithKline plc, Mylan N.V., Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Purdue Pharma L.P., Novartis AG, Johnson and Johnson

^*Terms and Conditions Apply